Stock Quote

Ascletis Doses First Person in US Trial of Novel NASH Treatment

Ascletis of Hangzhou announced its Gannex subsidiary has dosed the first person in a US Phase I trial of ASC42, its NASH treatment. ASC42 is a Farnesoid X Receptor (FXR) agonist. The trial is a randomized, double-blind, placebo-controlled, single and multiple dose escalation study designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics (biomarkers - FGF19 and C4) of ASC42 in healthy subjects. Ascletis described the candidate as a novel non-steroidal, selective and potent FXR agonist, with Fast Track designation from the US FDA for NASH. More details.... Stock Symbol: (HK: 1672) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.